NEW YORK, Oct. 2 - To stay attractive to venture capital investors and remain competitive, young genomic companies must have a broad platform that reduces their failure rate, they must be able to generate drug candidates, and they should be more frugal, according to some industry watchers. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.